Shares of Ascendis Pharma AS (NASDAQ:ASND) saw strong trading volume on Wednesday . 71,377 shares traded hands during mid-day trading, an increase of 34% from the previous session’s volume of 53,084 shares.The stock last traded at $18.45 and had previously closed at $18.45.

A number of equities research analysts have recently issued reports on the stock. Leerink Swann reissued an “outperform” rating and issued a $24.00 target price on shares of Ascendis Pharma AS in a research report on Thursday, May 26th. Zacks Investment Research raised shares of Ascendis Pharma AS from a “hold” rating to a “buy” rating and set a $17.00 target price for the company in a research report on Monday, August 15th.

The company’s market capitalization is $439.74 million. The company’s 50-day moving average price is $14.56 and its 200-day moving average price is $15.84.

Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop a pipeline of long-acting prodrug therapies that address markets with unmet medical needs. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.